[1] 卞留贯,孙青芳,沈建康,等.多发性神经纤维瘤病的临床和分子生物学研究[J].中华神经外科疾病研究杂志,2005,4:477-479. [2] Baser MF, Friedman JM, Wallace AJ, et al. Evaluation of clinical diagnostic criteria for neurofibromatosis[J]. Neurology,2002,59:1759-1765. [3] Sughrue ME,Yeung AH,Rutkowski MJ,et al. Molecular biology of familial and sporadic vestibular schwannomas:implications for novel therapeutics[J].J Neurosurg,2011,114:359-366. [4] Patel M, Ramasubramanian A. Introduction to pediatric genetic eye diseases[J].J Pediatr Genet,2014,3: 185-193. [5] Samii M, Gerganov V, Samii A. Microsurgery management of Vestibular schwannomas in neurofibromatosis type 2: indications and results[J].Prog Neurol Surg, 2008,21:169-175. [6] Szudek J, Briggs R, Leung R.Surgery for nerofibromatosis 2[J]. Curr 0pin 0tolaryngol Head Neck Surg, 2012, 20: 347-352. [7] Slattery WH, Hoa M, Bonne N, et al. Middle fossa decompIession for hearing preservation: a review of institutional results and indications[J]. Otol NeumtoI, 2011, 32: 1017-1024. [8] Friedman RA, Goddard JC, Wilkinson EP, et al.Hearing preservation with the middle cranial fossa approach for neurfibromatosis type 2[J]. Otol Neurotol, 2011, 32: 1530-1537. |